SEC Form 4 · accession 0001144204-16-105534
Lifeward Ltd. · LFWD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wayne Weisman
Director · 10% Owner
Period of report
May 25, 2016
Accepted (ET)
May 27, 2016 · 4:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607962
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value NIS 0.01 per shareF1,F2,F3 | May 25, 2016 | S | 12,022 | $8.7972 | D | 1,732,530 | I | By partnership |
| Ordinary Shares, par value NIS 0.01 per shareF4,F5,F3,F6,F7 | May 26, 2016 | S | 15,000 | $8.6071 | D | 1,717,530 | I | By partnership |
| Ordinary Shares, par value NIS 0.01 per shareF8 | holding | — | — | — | 6,022 | I | ESOP |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The disposed of securities consist of 9,012 Ordinary Shares sold by SCP Vitalife Partners II, L.P. ("SCP Vitalife") and 3,010 shares sold by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife Israel").
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.7000 to $8.9600, inclusive. The reporting person undertakes to provide to ReWalk Robotics, Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The Reporting Person is a director of SCP Vitalife II GP, Ltd. ("SCP Vitalife GP"), which is the sole general partner of SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"). SCP Vitalife Associates is the sole general partner of each of SCP Vitalife and SCP Vitalife Israel, the direct beneficial owner of the Ordinary Shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the Ordinary Shares held by SCP Vitalife and SCP Vitalife Israel, except to the extent of his pecuniary interest therein.
- F4The disposed of securities consist of 11,244 Ordinary Shares sold by SCP Vitalife and 3,756 shares sold by SCP Vitalife Israel.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.6000 to $8.6600, inclusive. The reporting person undertakes to provide to ReWalk, any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
- F6As of May 27, 2016, SCP Vitalife Associates, as the general partner of SCP Vitalife and SCP Vitalife Israel, may be deemed to beneficially own 1,575,004 Ordinary Shares, which consist of 1,180,665 and 394,339 Ordinary Shares held by SCP Vitalife and SCP Vitalife Israel, respectively. SCP Vitalife GP is the general partner of SCP Vitalife Associates and, as such, shares voting and dispositive power over, and may be deemed to beneficially own, the Ordinary Shares held by the foregoing entities. The Reporting Person shares voting and dispositive power over, and may be deemed to beneficially own 1,717,530 Ordinary Shares, which consist of the Ordinary Shares as set forth in footnote (7) to this Form 4.
- F7As of May 27, 2016, consists of 1,575,004 Ordinary Shares held by the foregoing entities due to the Reporting Person serving as a director of SCP Vitalife GP, as well as (i) 62,006 Ordinary Shares held by Vitalife Partners (Overseas) L.P., (ii) 20,506 Ordinary Shares held by Vitalife Partners (Israel) L.P., (iii) 20,733 Ordinary Shares held by Vitalife Partners (D.C.M) L.P. ("Vitalife Partners DCM", and together with Vitalife Partners (Overseas) L.P. and Vitalife Partners (Israel) L.P., the "Vitalife I Entities") and (iv) 39,281 Ordinary Shares currently held by the Office of the Chief Scientist of the State of Israel ("OCS"), that the Vitalife I Entities have the right to acquire from the OCS, due to the Reporting Person serving as a director of Vitalife Life Sciences Ltd., the general partner of Vitalife Partners Management L.P., which is the general partner of each of the Vitalife I Entities.
- F8Represents 6,022 ordinary shares issuable upon the vesting of restricted stock units ("RSUs") granted on December 15, 2014 under the ReWalk 2014 Equity Incentive Plan. One-third, or 2,007 Ordinary Shares, of the RSUs vested on the first anniversary of the date of grant and the remaining RSUs vest in equal quarterly installments of 501 Ordinary Shares each starting one quarter after the first anniversary of the date of grant.